A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia

Blood

Volumn 124, Issue 9, 2014, Pages 1434-1444

  Moorman, Anthony V ^a   Enshaei, Amir ^a   Schwab, Claire ^a   Wade, Rachel ^b   Chilton, Lucy ^a   Elliott, Alannah ^a   Richardson, Stacey ^a   Hancock, Jeremy ^c   Kinsey, Sally E ^d,e   Mitchell, Christopher D ^f   Goulden, Nicholas ^g   Vora, Ajay ^h   Harrison, Christine J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NORTH BRISTOL NHS TRUST   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX5; BTG1 PROTEIN, HUMAN; ONCOPROTEIN; PAX5 PROTEIN, HUMAN; REPRESSOR PROTEIN; TEL-AML1 FUSION PROTEIN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR RUNX1; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COHORT ANALYSIS; COPY NUMBER VARIATION; CYTOGENETICS; DIPLOIDY; EVENT FREE SURVIVAL; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC RISK; GENOMICS; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; CLASSIFICATION; GENE DOSAGE; GENETICS; INFANT; KAPLAN MEIER METHOD; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; RISK FACTOR; TUMOR SUPPRESSOR GENE; VALIDATION STUDY;

ADOLESCENT; B-CELL-SPECIFIC ACTIVATOR PROTEIN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOGENETIC ANALYSIS; FEMALE; GENE DELETION; GENE DOSAGE; GENES, P16; GENOMICS; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; RISK FACTORS;

EID: 84907360666     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-562918     Document Type: Article

References (37)

1. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26(3):123-135.
2. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11(5):429-438.
3. Mullighan CG, Goorha S, Radtke I, et al. Genomewide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137):758-764.
4. Schwab CJ, Chilton L, Morrison H, et al. Genes commonly deleted in childhood B-cell precursor ALL: association with cytogenetics and clinical features. Haematologica. 2013;98(7):1081-1088.
5. Mullighan CG, Su X, Zhang J, et al; Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
6. Dörge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98(3): 428-432.
7. Palmi C, Valsecchi MG, Longinotti G, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphianegative B-cell precursor acute lymphoblastic leukemia? Haematologica. 2013;98(8): 1226-1231.
8. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010;24(7):1258-1264.
9. Ensor HM, Schwab C, Russell LJ, et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011;117(7): 2129-2136.
10. Cario G, Zimmermann M, Romey R, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-highrisk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010;115(26): 5393-5397.
11. Palmi C, Vendramini E, Silvestri D, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia. 2012;26(10): 2245-2253.
12. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012;119(15): 3512-3522.
13. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010;116(23):4874-4884.
14. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2): 125-134.
15. van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622- 2629.
16. Vora A, Goulden N, Wade R, et al. A randomised trial of treatment reduction for children and young adults with minimal residual disease defined low risk acute lymphoblastic leukaemia. Lancet Oncol. 2013;14(3):199-209.
17. Vora A, Mitchell CD, Lennard L, et al; Medical Research Council; National Cancer Research Network Childhood Leukaemia Working Party. Toxicity and efficacy of 6-thioguanine versus 6- mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 2006; 368(9544):1339-1348.
18. van der Velden VH, Cazzaniga G, Schrauder A, et al; European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4): 604-611.
19. Schwab CJ, Jones LR, Morrison H, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49(12): 1104-1113.
20. Familiades J, Bousquet M, Lafage-Pochitaloff M, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia. 2009;23(11): 1989-1998.
21. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-2698.
22. Russell LJ, Enshaei A, Jones L, et al. IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. J Clin Oncol. 2014;32(14):1453-1462.
23. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330): 356-361.
24. Zaliova M, Zimmermannova O, Dörge P, et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia. 2014; 28(1):182-185.
25. Clappier E, Auclerc MF, Rapion J, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014;28(1):70-77.
26. Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118(11):3080-3087.
27. Case M, Matheson E, Minto L, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008;68(16):6803-6809.
28. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3): 242-252.
29. Mühlbacher V, Zenger M, Schnittger S, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer. 2014;53(6):524-536.
30. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitorand Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11): 1243-1246.
31. Waanders E, van der Velden VH, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia. 2011; 25(2):254-258.
32. Pichler H, Möricke A, Mann G, et al; Berlin-Frankfurt-M ünster (BFM) Study Group. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt- Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. Br J Haematol. 2010;149(1):93-100.
33. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165-1174.
34. Moorman AV, Robinson H, Schwab C, et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol. 2013;31(27):3389-3396.
35. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012; 22(2):153-166.
36. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(25):e413-e416.
37. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1- PDGFRB fusion. Haematologica. 2013;98(11): e146-e148.